EUVIMEDEUVIMED entdecken
Crossref

Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Studies Related to Vincristine‐Induced Peripheral Neuropathy in Chinese Pediatric ALL Patients

Yawen Yuan iD, Wenting Hu iD, Changcheng Chen iD, Ruen Yao iD, Shunguo Zhang iD, Xiao Zhu iD, Bulong Xu iD, Zhonghui Huang iD, Shengyuan Zhang iD, Xuexian Wang iD, Mei Zheng iD, Xiaohui Huang iD und 1 weitere

Clinical Pharmacology & Therapeutics · 2025-02 · 117 (2) · 454-464

DOI: 10.1002/cpt.3462 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 04.10.2024. Verfasst von Yawen Yuan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Phytogenic, Peripheral Nervous System Diseases, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Vincristine. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vincristine (VCR) can cause vincristine‐induced peripheral neuropathy (VIPN) during the treatment of acute lymphoblastic leukemia (ALL) and the mechanisms are complicated. The aim of this study was to investigate the influencing factors on the population pharmacokinetics (PopPK) and pharmacodynamics (PD) related to VIPN, including clearance routes, drug–drug interactions (DDI), and genetic characteristics. Pediatric patients being treated for ALL were recruited to PK study where VCR and its metabolite (M1) were measured using a novel assay. The incidence of VIPN was also recorded. DNA sequencing of relevant PK and PD genes was performed. PopPK and PK/PD models were developed, pharmacogenetic and DDI analyses were conducted. In total, 79 children were recruited. The results showed that allometric scaling, ABCB1‐rs1128503 genotype, and posaconazole (POS) significantly improved the PopPK model fit. VIPN was significantly correlated with the exposure of VCR. Co‐administration with POS shifted the effect curve for VIPN to the left, indicating increased VIPN risk at the same exposure levels. No significant effects on VIPN were observed for CYP3A5 (rs776746), CYP3A4 (rs2242480), CEP72 (rs924607), or various ABCB1 variants (rs1128503, rs2032582, rs1045642, rs4728709, rs4148737, and rs10276036), nor with the co‐administration of fluconazole or dasatinib. In summary, co‐administration of POS increased VCR exposure by 0.4‐fold and raised the risk of VIPN, with an occurrence probability generally exceeding 0.7. Therapeutic drug monitoring of VCR in clinical practice may be necessary to enable appropriate dose adjustments and individualized treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Agents, PhytogenicPeripheral Nervous System DiseasesPrecursor Cell Lymphoblastic Leukemia-LymphomaVincristineAdolescentChildChild, PreschoolFemaleHumansInfantMaleATP Binding Cassette Transporter, Subfamily BChinaCytochrome P-450 CYP3ADrug InteractionsGenotypeModels, BiologicalPharmacogeneticsPharmacogenomic TestingEast Asian People

Substanzen

ABCB1 protein, humanAntineoplastic Agents, PhytogenicATP Binding Cassette Transporter, Subfamily BCytochrome P-450 CYP3AVincristine

Autor:innen und Institutionen

  • Department of Pharmacy, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Infection, Immunity, Inflammation Section, UCL Institute of Child Health, London, UK.
  • Department of Hematology/Oncology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Department of Medical Genetics, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China.
  • Department of Clinical Pharmacy, School of Medicine, Xinhua Hospital, Shanghai Jiao Tong University, Shanghai, China.

ORCID-Profile: Yawen Yuan, Wenting Hu, Changcheng Chen, Ruen Yao, Shunguo Zhang, Xiao Zhu, Bulong Xu, Zhonghui Huang, Shengyuan Zhang, Xuexian Wang, Mei Zheng, Xiaohui Huang, Joseph F Standing

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Yuan, Y., Hu, W., Chen, C., Yao, R., Zhang, S., Zhu, X., Xu, B., Huang, Z., Zhang, S., Wang, X., Zheng, M., Huang, X., & Standing, J. F. (2025). Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Studies Related to Vincristine‐Induced Peripheral Neuropathy in Chinese Pediatric ALL Patients. Clinical Pharmacology & Therapeutics, 117(2), 454-464. https://doi.org/10.1002/cpt.3462

Vancouver

Yuan Y, Hu W, Chen C, Yao R, Zhang S, Zhu X, et al. Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Studies Related to Vincristine‐Induced Peripheral Neuropathy in Chinese Pediatric ALL Patients. Clinical Pharmacology & Therapeutics. 2025;117(2):454-464. doi:10.1002/cpt.3462

BibTeX
@article{Yuan2025,
  author = {Yuan, Yawen and Hu, Wenting and Chen, Changcheng and Yao, Ruen and Zhang, Shunguo and Zhu, Xiao and Xu, Bulong and Huang, Zhonghui and Zhang, Shengyuan and Wang, Xuexian and Zheng, Mei and Huang, Xiaohui and Standing, Joseph F},
  title = {Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Studies Related to Vincristine‐Induced Peripheral Neuropathy in Chinese Pediatric ALL Patients},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  volume = {117},
  number = {2},
  pages = {454--464},
  doi = {10.1002/cpt.3462}
}
Kostenlos starten →